• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
The New Trends of Global Drug Discovery Outsourcing 2013 Product Image

The New Trends of Global Drug Discovery Outsourcing 2013

  • ID: 2669677
  • September 2013
  • Region: Global
  • 200 Pages
  • JZMed Inc

After having focused on the late stage drug development for several years, the global major pharmaceutical and biopharmaceutical companies have now all realized that they need to refocus on early stage pipelines. Drug discovery has thus regained the focus of all major pharma and biopharma companies.

However, their research strategy in this field has undergone significant changes over the last couple of years. All drug companies have now recognized that early stage drug discovery is not just to identify a new chemical entity for a target; rather, it is about the validation of the identified therapeutic target and better understanding of the disease biology and pathology as well as the interactions between the compound and the target as well as those off-targets. Biology-guided drug discovery has thus become a new trend of drug R&D in today’s pharmaceutical industry. Moreover, as they are now in a desperate need to develop better drugs with high success rates, all drug companies increasingly utilize the external resources while still constantly streamlining their internal operation. In fact today externalization has become a core strategy among all major pharma and biopharma READ MORE >

Scope of the Report

About Author

Executive Summary

- The new R&D strategies of global major pharmaceutical and biopharmaceutical companies
- The new drug discovery outsourcing strategies of global pharmaceutical and biopharmaceutical companies
- The new trends of drug discovery outsourcing in emerging countries
- Future growth outlook of global drug discovery outsourcing market

Chapter One - The New R&D Strategies of Global Major Pharmaceutical and Biopharmaceutical Companies

Summary
1.1 Introduction
1.2 A new era of global pharmaceutical industry resulting from significant changes in drug R&D strategy
1.3 Drug discovery research and early stage development regaining focus of major pharma/biopharma companies
1.4 Biologic drug R&D becoming a new focus among all global major pharma companies
1.5 Drug discovery and development becoming more genomics-based
1.5.1 Human genetic information increasingly employed in drug R&D
1.5.2 Genomics testing becoming increasingly involved in clinical trials
1.5.3 Biomarkers being widely applied in almost every stage of drug R&D
1.6 New R&D strategies of major pharma/biopharma companies
1.6.1 Networked Partnership
1.6.2 Open Source Innovation
1.6.3 Disease biology becoming key to drug discovery ? “Biologic Probes”
1.6.4 Focusing more on new technologies
1.6.5 Turning sponsor-service provider relationship to partnership
1.6.6 R&D consortium becoming popular
1.6.7 More willing to collaborate with peer competitors
1.6.8 Academia becoming one of three key elements in global drug R&D
1.6.9 Dual-track drug discovery approach on both small molecules and biologics
1.7 New R&D strategies starting showing improvements in R&D productivity

Chapter Two - The New Drug Discovery Outsourcing Strategies of Global Pharmaceutical and Biopharmaceutical Companies

Summary
2.1 Introduction
2.2 New trend of drug discovery research – Integrated research model
2.3 Latest technology developments for small molecule drug discovery research and outsourcing
2.3.1 Compound library screening still a major tool for quick discovery of leads but drug companies desiring new libraries with unique structural features
2.3.2 Fragment-based lead discovery approach still popularly employed
2.4 Latest technology developments for biologic drug discovery research and outsourcing
2.4.1 Comparison of research methodologies between small molecule drug discovery and biologic drug discovery
2.4.2 New technological development trends in biologic drug discovery
2.5 Latest trends of global small molecule drug discovery outsourcing
2.5.1 New trends in medicinal chemistry research outsourcing
2.5.2 New trends in target identification/validation outsourcing
2.5.3 New drug discovery outsourcing strategy: Integrated drug discovery outsourcing
2.6 Latest trends of global biologic drug discovery outsourcing
2.6.1 Strong demands for biological compound libraries
2.6.2 Major pharma/biopharma companies increasingly licensing new technologies from specialty biotech companies
2.7 New trends of major pharma/biopharma companies’ drug discovery outsourcing demands and strategies
2.7.1 New strategies of major pharma/biopharma companies on small molecule drug discovery outsourcing
1. Mechanism-targeting biology research now closely incorporated with discovery research
2. Virtual research model on small molecule drug discovery
3. Selectively choosing preferred service providers as their close partners
2.7.2 New strategies of major pharma/biopharma companies on biologic drug discovery outsourcing
1. Latest trends of major pharma/biopharma companies in therapeutic antibody drug discovery outsourcing
2. Latest trends of major pharma/biopharma companies in antibody-drug conjugate (ADC) discovery outsourcing
3. Latest trends of major pharma/biopharma companies in therapeutic peptide drug discovery outsourcing
2.8 New trends of small biotech companies’ drug discovery outsourcing demands and strategies
2.8.1 Small biotech companies’ outsourcing demands for small molecule drug discovery service
2.8.2 Small biotech companies’ outsourcing demands for biologic drug discovery service
2.9 Drug discovery service demands by non-profit organizations ? A new trend emerging in recent years
2.10 New developments in drug discovery outsourcing services
2.10.1 CROs expanding service scopes and increasing service capabilities
2.10.2 More academics providing drug discovery research service like professional CROs
2.10.3 Drug discovery service CROs offering risk-sharing services

Chapter Three - The New Trends of Drug Discovery Outsourcing in Emerging Countries

Summary
3.1 Introduction
3.2 Attractions of emerging markets to global drug companies
3.3 New R&D strategies of global major pharma/biopharma companies in emerging markets
3.4 New trends of small molecule drug discovery outsourcing in China
3.4.1 Major pharma/biopharma companies’ current R&D strategies in China
3.4.2 New trends of major pharma/biopharma companies collaborating with Chinese organizations on small molecule drug discovery research
3.4.3 New trends of multinational small biotech companies collaborating with Chinese companies on small molecule drug discovery research
3.5 New trends of small molecule drug discovery outsourcing in India
3.5.1 Current R&D strategies of major pharma/biopharma companies in India
3.5.2 New trends of major pharma/biopharma companies collaborating with Indian companies on small molecule drug discovery research
3.5.3 Multinational small biotech companies collaborating with Indian companies on small molecule drug discovery research
3.6 New trends of drug discovery outsourcing in other emerging countries
3.7 Current states of biologic drug discovery outsourcing in emerging countries
3.7.1 Current state of biologic drug R&D in China
3.7.2 Current state of biologic drug R&D in India
3.7.3 Current state of multinational pharma/biopharma companies outsourcing biologic drug discovery research in China and India
3.8 Comparison of drug discovery outsourcing between developed countries and emerging countries

Chapter Four - Future Growth Outlook of Global Drug Discovery Outsourcing Market

Summary
4.1 Introduction
4.2 Analysis of current global drug discovery outsourcing market
4.2.1 Analysis of current drug discovery outsourcing penetrations in global pharmaceutical and biopharmaceutical industries
4.2.2 Current global drug discovery outsourcing market size
4.2.3 Current drug discovery outsourcing markets in emerging countries and their shares in total global drug discovery outsourcing market
1. Current market size of small molecule drug discovery outsourcing in emerging countries
2. Current market size of biologic drug discovery outsourcing in emerging countries
3. Current shares of emerging countries in total global drug discovery outsourcing market
4.3 Analysis of possible future drug R&D strategies of global major pharma/biopharma companies
4.4 Analysis of future drug R&D budget growth potentials of world pharmaceutical industry
4.5 Analysis of future drug discovery outsourcing demands of global drug companies
4.5.1 Future drug discovery outsourcing service demands by major pharma/biopharma companies
1. Major pharma/biopharma companies’ future outsourcing service demands for small molecule drug discovery research
2. Major pharma/biopharma companies’ future outsourcing service demands for biologic drug discovery research
4.5.2 Future drug discovery outsourcing service demands by small biotech companies
4.6 Analysis of future growth potentials of global drug discovery outsourcing market
4.6.1 Forecast of future growth potentials of global small molecule drug discovery outsourcing market
4.6.2 Forecast of future growth potentials of global biologic drug discovery outsourcing market
4.7 Analysis of future growth potentials of global drug discovery outsourcing penetration
4.7.1 Analysis of future growth potential of overall global drug discovery outsourcing penetration
4.7.2 Analysis of future growth potential of global small molecule drug discovery outsourcing penetration
4.7.3 Analysis of future growth potential of global biologic drug discovery outsourcing penetration
4.8 Analysis of future growth potentials of drug discovery outsourcing market in emerging countries
4.8.1 Forecast of future growth potentials of small molecule drug discovery outsourcing market in emerging countries
4.8.2 Forecast of future growth potentials of biologic drug discovery outsourcing market in emerging countries
4.9 Analysis of different future drug discovery outsourcing demands by global drug companies in developed countries and emerging countries
4.10 Analysis of possible future drug discovery research strategies and outsourcing patterns
4.10.1 Broader networked partnerships with more external resources
4.10.2 Virtual drug discovery research model
4.10.3 Biologic drug discovery will be equally focused as small molecules
4.10.4 Higher demands for generation and fast screening of antibody libraries
4.10.5 New drug discovery protocols ? Screening therapeutic targets against fully evaluated compounds
4.10.6 Drug design will be more guided by biomarkers and related genomics/proteomics research

Appendix

Appendix I. Research Methodology

Appendix II. About JZMed, Inc.

List of Tables

Table 1. R&D strategy changes of global major pharma companies over past several years
Table 2. New development trends of global biopharmaceutical industry
Table 3. Criteria of major pharma/biopharma companies choosing preferred service providers
Table 4. Recent examples of partnership between small biotech companies and academic institutions
Table 5. Increasing involvement of academics in global drug R&D industry
Table 6. Current proportions of biologic drugs in pipelines of major pharma companies
Table 7. New trends of global drug R&D
Table 8. Advantages of externalization
Table 9. Technologies required for integrated drug discovery research
Table 10. Current status of small molecule compound libraries in global drug discovery research
Table 11. Comparisons between fragment-based lead discovery (FBLD) approach and high-throughput screen (HTS) approach
Table 12. Comparison of drug discovery research process between small molecules and biologics
Table 13. Special considerations when moving a biologic drug from discovery to development
Table 14. Current states of drug discovery research and outsourcing in global pharmaceutical industry
Table 15. Current trends of global biologic drug discovery outsourcing
Table 16. Drug discovery service demanded by non-profit organizations
Table 17. New trends evolving in global drug discovery outsourcing industry
Table 18. Key advantages of emerging markets
Table 19. Benefits of entering emerging markets
Table 20. Common goals of major pharma/biopharma companies in emerging countries
Table 21. Major pharma/biopharma companies having (or planning to have) Asia-Pacific operating (or R&D) headquarters in China
Table 22. Examples of major pharma/biopharma companies operating their R&D within Chinese CRO’s facilities
Table 23. Major pharma/biopharma companies’ new China R&D strategies
Table 24. Common outsourcing models of multinational biotech companies in China
Table 25. Examples of major partnerships forged in recent years between major pharma/biopharma companies and Indian companies on drug discovery research
Table 26. More examples of collaboration between major pharma/biopharma companies and drug companies/CROs in other emerging countries than China and India
Table 27. Comparisons of advantages and disadvantages of conducting drug discovery outsourcing in developed countries and emerging countries
Table 28. Current value and past growth history of total global drug discovery outsourcing market (including markets for small molecule drug discovery outsourcing and biologic drug discovery outsourcing)
Table 29. Analysis of market values and shares of each subtype of drug discovery service in total global drug discovery outsourcing market
Table 30. Current values and past growth histories of small molecule drug discovery outsourcing market in China and India
Table 31. Current values and past growth trends of biologic drug discovery outsourcing market in China and India
Table 32. Analysis of market shares of each subtype of drug discovery research service performed by emerging countries in total global drug discovery outsourcing market
Table 33. Necessity and benefits for pharmaceutical industry to collaborate with academia on drug R&D
Table 34. Latest R&D strategies of global major pharma/biopharma companies
Table 35. Anticipated future drug R&D strategies likely adopted by global major pharma/biopharma companies
Table 36. Global drug R&D spendings during 2005?2009
Table 37. Analysis of future growth potentials of drug R&D budget of world pharmaceutical industry
Table 38. Predictions of global drug R&D budget growth in following five years
Table 39. Analysis of future growth drivers of global small molecule drug discovery outsourcing market
Table 40. Forecasted future growth of global small molecule drug discovery outsourcing market
Table 41. Forecasted future growth of global biologic drug discovery outsourcing market
Table 42. Predictions of global R&D budget growths on drug discovery research in following seven years
Table 43. Forecasted future growths of global drug discovery outsourcing penetration
Table 44. Current strengths of emerging countries in small molecule drug discovery research
Table 45. Forecasted future growths of small molecule drug discovery outsourcing market in emerging countries
Table 46. Forecasted future growths of biologic drug discovery outsourcing market in emerging countries
Table 47. Comparisons of drug R&D success rates in various development stages between biologics and small molecules
Table 48. Analysis of future drug R&D directions of world pharmaceutical industry

List of Figures

Figure 1. Past growth trends of global drug discovery outsourcing market
Figure 2. Past growth trends of small molecule drug discovery outsourcing markets in China and India
Figure 3. Forecasted future growth trend of global small molecule drug discovery outsourcing market
Figure 4. Forecasted future growth trend of global biologic drug discovery outsourcing market
Figure 5. Model predictions of global drug discovery outsourcing market and penetration by 2020
Figure 6. Forecasted future growth trends of outsourcing penetration in global drug discovery research
Figure 7. Forecasted future growth trends of small molecule drug discovery outsourcing market in emerging countries
Figure 8. Forecasted future growth trends of biologic drug discovery outsourcing market in emerging countries

List of Case Studies

Case Study 1. Drug R&D would not have been that costly if failure rate could be reduced
Case Study 2. New R&D strategies implemented by GSK
Case Study 3. Example of major pharma/biopharma companies emphasizing importance of external resources to their R&D effort
Case Study 4. Examples of major pharma/biopharma companies signing collaboration contracts with biotech companies to refocus on drug discovery research
Case Study 5. Amgen acquired deCODE Genetics to enhance its genomics research
Case Study 6. Examples of major pharma/biopharma companies increasingly utilizing external resources
Case Study 7. Major pharma/biopharma companies’ crowd-sourcing strategy
Case Study 8. Major pharma/biopharma companies’ new R&D strategies
Case Study 9. Pfizer’s CTI model ? Focusing on disease biology and primarily relying on academics
Case Study 10. Biomarkers have become a hot outsourcing area in toxicology research
Case Study 11. AstraZeneca and Bayer granted each other access to screening their compound libraries
Case Study 12. Pfizer’s new R&D unit – Centers for Therapeutic Innovation (CTI)
Case Study 13. Dual-track drug discovery programs run by major pharma/biopharma companies
Case Study 14. Private and public efforts to accelerate drug discovery progress in Europe
Case Study 15. New technologies developed by biotech companies and increasingly licensed by major pharma/biopharma companies for novel antibody drug discovery
Case Study 16. Major pharma/biopharma companies licensing antibody drug discovery technologies from biotechnology specialist companies
Case Study 17. Pharma company’s virtual drug discovery strategy
Case Study 18. Virtual drug discovery research model of AstraZeneca’s neuro-therapeutic programs
Case Study 19. Major pharma/biopharma companies collaborating with CROs on small molecule drug discovery research
Case Study 20. Analysis of Eli Lilly’s small molecule drug discovery outsourcing strategies
Case Study 21. Major pharma and biopharma companies increasingly outsourcing antibody drug discovery research
Case Study 22. Examples of major pharma/biopharma companies partnering with ADC specialist biotech companies on ADC discovery
Case Study 23. Examples of drug discovery collaboration between major pharma/biopharma companies and biotech companies focusing on peptide drugs
Case Study 24. A semi-virtual US biotech company outsourcing drug discovery research to China
Case Study 25. Small biopharma companies outsourcing mAb drug discovery research
Case Study 26. Example of drug discovery service CROs rapidly expanding their service scope and enhancing their service capability
Case Study 27. Drug discovery service CROs offering risk-sharing outsourcing service model
Case Study 28. Major pharma/biopharma companies showing greater interests to partner with Asian organizations
Case Study 29. Example of major pharma companies collaborating with Chinese organizations for natural product libraries
Case Study 30. Major pharma/biopharma companies deciding to establish full-scale R&D centers in China
Case Study 31. Major pharma/biopharma companies licensing drug candidates to Chinese drug companies for co-development in China
Case Study 32. Eli Lilly extending and expanding partnership with ShangPharma in small molecule drug discovery research
Case Study 33. Example of major pharma/biopharma company collaborating with Chinese university on innovative drug R&D
Case study 34. Major pharma/biopharma companies contracting out drug discovery research to Chinese CROs
Case Study 35. AstraZeneca signing multi-year contract with Pharmaron on drug discovery collaboration
Case Study 36. More examples of major pharma/biopharma companies collaborating with Chinese organizations on drug discovery research
Case Study 37. Merck collaborating with BGI on biomarker and genomic research
Case Study 38. A US biotech company outsourcing drug discovery research to China
Case Study 39. More examples of small biotech companies outsourcing drug discovery research to China
Case Study 40. Long term collaboration between BMS and Syngene on drug discovery and development
Case Study 41. US-based biotech company forging risk-sharing drug discovery collaboration with GVK Biosciences
Case Study 42. Major pharma/biopharma companies partnering with CROs in East Europe for drug discovery research
Case Study 43. Current novel mAb drug R&D programs of Shanghai CP Guojian Pharmaceutical
Case Study 44. R&D capability of a typical Chinese biopharma company
Case Study 45. Current mAb drug R&D activities of major Indian biopharma companies
Case Study 46. Domestic Chinese biopharma companies outsourcing mAb drug discovery research to local bio-CROs
Case Study 47. Analysis of future growth potentials of biopharma outsourcing service of WuXi PharmaTech
Case Study 48. Multinational CROs attempting to enter emerging markets with limited success
Case Study 49. Major Pharma/biopharma companies increasing their R&D focus on biologic drugs
Case Study 50. Virtual drug R&D model accepted by major pharma/biopharma companies
Case Study 51. Virtual drug discovery research model has become feasible

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos